an update
INTRODUCTION
Inherited thrombocytopenias are clinically and genetically heterogeneous diseases, caused by mutations in numerous disease-causing genes that encode for a variety of molecules. However, mutations in the known inherited thrombocytopenia genes account for approximately 50% of the patients, suggesting extremely wide genetic heterogeneity. Therefore, identification of novel genes is fundamental to characterize novel platelet disorders and improve our knowledge on the physiological mechanisms involved in megakaryopoiesis and platelet formation.
Next-generation sequencing (NGS) is a revolutionary technique that has been providing significant breakthroughs in the molecular bases of Mendelian diseases, including inherited thrombocytopenias. In recent years, its application has allowed identification of several genes, such as NBEAL2 and RBM8A, whose mutations are responsible for well-known diseases (gray platelet syndrome and thrombocytopenia and absent radii, respectively) or ACTN1, GFI1B, and PRKACG implicated in novel and less-characterized forms of inherited thrombocytopenias [1] . Even in the last year, the most important discoveries are mainly due to NGS. The novel genes encode for transcription factors, components of the cytoskeleton, players of signaling pathways, or molecules of unknown function in the platelet formation process. It is also worth mentioning that the identification of variants in two known inherited thrombocytopenia genes, FLI1 and ACTN1, extends insights into the
TRANSCRIPTION FACTORS
Different genes encoding for transcription factors, such as RUNX1, ETV6, FLI1, GATA1, or GFI1B, are involved in inherited thrombocytopenias [1] . Their mutations are usually associated with defective maturation of megakaryocytes, which are usually increased in number and immature.
Another transcription factor involved in inherited thrombocytopenia is HOXA11. For at least 15 years, its unique mutation p.Asn291ThrfsÃ4 has been the only variant known in radioulnar synostosis associated with amegakaryocytic thrombocytopenia (RUSAT) [2] . The syndrome was known to be genetically heterogeneous but the second gene, MECOM, has been identified only recently [3 && ]. As the affected individuals carry de-novo missense mutations (p.Thr756Ala, p.His751Arg, and p.Arg750Trp), this atypical model of inheritance is likely to have prevented cloning the gene until the recent application of NGS. Even MECOM encodes for a transcriptional regulator protein (EVI1), recruiting either coactivators or corepressors. EVI1 contains 10 zinc finger domains -seven at the N-terminal and three at the C-terminal regions. The three mutations affect the eighth motif and they might alter the DNA-binding affinity of the C-terminal domain [3 && ]. Differently from the mutations affecting the inherited thrombocytopenia transcription factors, those in HOXA11 and MECOM cause defects in the early phase of megakaryopoiesis. In fact, RUSAT is a rare autosomal dominant inherited thrombocytopenia characterized by severe thrombocytopenia due to absence or significant reduction of megakaryocytes. It might evolve into aplastic anemia, necessitating bone marrow or umbilical cord stem cell transplantation. Interestingly, EVI1 inhibits the expression of RBM8A, the gene responsible for thrombocytopenia-absent radius syndrome, which together with RUSAT are the only thrombocytopenias associated with skeletal defects [4] . RBM8A encodes for RNA-binding protein 8A, a subunit of the exon-junction complex that is required for mRNA metabolism processes, such as splicing, mRNA export, and nonsense-mediated mRNA decay. However, the role of both EVI1 and RBM8A in platelet formation should be further investigated.
Another discovery worthy of mention regards FLI1, which -like ETV6 -is a transcription factor of the EST family. FLI1 is localized at the terminal region of chromosome 11 (11q24.3), whose hemizygous condition causes the Jacobsen syndrome characterized by several developmental abnormalities. A large majority of these patients suffer from thrombocytopenia and platelet dysfunction (known as Paris-Trousseau syndrome) [5] . The hypothesis that haploinsufficiency of FLI1 is responsible for thrombocytopenia was supported by detection of heterozygous mutations (p.Asn331thrfsÃ4, p.Arg337Trp, and p.Tyr343Cys) in families with isolated bleeding tendency [6] . However, the recent identification of a FLI1 homozygous (p.Arg324Trp) mutation in two affected sisters with consanguineous unaffected parents has provided evidence for an autosomal recessive transmission of thrombocytopenia [7 && ]. Of note, the two patients share the same phenotype as that of individual hemizygous at 11q24.3 or with monoalleic mutations of FLI1. They have a lifelong history of moderate thrombocytopenia with excessive bleeding. Their platelets are increased in size with giant alpha-granules arisen from fusion of smaller organelles and exhibit abnormal response to traditional agonists such as collagen and ADP. Functional studies demonstrated that p.Arg324Trp leads to decreased transcriptional activity of the genes targeted by FLI1 and to concomitant reduction of their respective protein expression level. As the parents of the two affected sisters are asymptomatic, the variant is likely to be hypomorphic in comparison with the others identified in the FLI1 gene. Interestingly, the point FLI1 mutations affect highly conserved residues of the ETS domain, which directly interacts with DNA. Although residue Arg324 interacts with the N-terminal autoinhibitory domain regulating DNAbinding affinity, the other mutations are predicted to disrupt the ETS region. Considering that transient monoallelic expression of FLI1 is critical for megakaryocyte development [8] , the mechanisms governing the thrombocytopenia associated with alterations of FLI1 remain unclear.
KEY POINTS
Next-generation sequencing (NGS) is significantly increasing the number of mutations in genes responsible for inherited thrombocytopenias (ITs).
In the last year, six novel genes and diseases have been discovered, further improving our knowledge on the pathogenetic mechanisms of IT.
Identification of hypomorphic mutations and SNPs associated with reduced platelet production leads to consider ITs as not only monogenic but also polygenic traits.
Continuous use of NGS combined with functional studies will allow us to extend the molecular bases of ITs, half of which are yet uncharacterized. Table 1 . Discoveries on inherited thrombocytopenias: identification of novel genes MECOM, DIAPH1, TRPM7, SRC, FYB, and SLFN14 and the role of novel variants in known inherited thrombocytopenia (FLI1 and ACTN1) genes. To complete information on genes (FLI1 and ACTN1) or diseases (radioulnar synostosis with amegakaryocytic thrombocytopenia), additional data are reported 
CYTOSKELETON COMPONENTS
The largest group of inherited thrombocytopenias is associated with defects of proplatelet formation and platelet release, a process that involves dynamic reorganization of the cytoskeleton in mature megakaryocytes. Indeed, mutations of genes, such as MYH9, ACTN1, WAS, TUBB1, and FLNA, known to encode for different components of cytoskeleton, are responsible for inherited thrombocytopenias [1] . Among recent discoveries within this group is the cloning of two novel genes, DIAPH1 and TRPM7, as well as the identification of a relatively common single nucleotide polymorphism (SNP) in the ACTN1 gene associated with reduction of the platelet count. Regarding DIAPH1, the same mutation (p.Arg1213Ã) has been identified in two unrelated families with an autosomal dominant inherited thrombocytopenia associated with hearing impairment (DIAPH1-related disease; DIAPH1-RD) [9 && ]. DIAPH1 encodes diaphanous-related formin 1, an effector of the small guanosine triphosphate (GTP)-binding protein known as a regulator of megakaryocytopoiesis, in vitro controlling cytoskeleton reorganization [10] . The mutation destroys the diaphanous autoregulatory domain (DAD), which interacting with diaphanous inhibitory domain inhibits the DIAPH1 activity and prevents cytoskeleton from remodeling with increased proplatelet formation from patients' cultured megakaryocytes [9 && ]. Affected platelets, which are large in size, show cytoskeleton alterations, such as excess of actin filaments and stable microtubules, reproducible in vitro. The DAD domain is also affected by a frameshift alteration identified in a large family with nonsyndromic hearing impairment [11] , suggesting that mutations in different domains of the protein might be responsible for different clinical phenotypes.
Macrothrombocytopenia and hearing loss, but also cataract and renal failure, are features of MYH9-related disease (MYH9-RD) [12] . MYH9-RD is a relatively common inherited thrombocytopenia caused by mutations of MYH9, a gene encoding for the heavy chain that after dimerization and association with two pairs of regulatory and essential light chains generates nonmuscle myosin IIA [13] . This hexameric molecule assumes a compact form that is unable to associate with others to form bipolar filaments. After phosphorylation of the regulatory chains, the compact molecules unfold and organize in bipolar filaments for actomyosin-based contraction. Like in DIAPH1-RD, megakaryocytes from MYH9-RD patients show an increased proplatelet formation, suggesting that myosin IIA has inhibitory effect on this process and that premature release of platelets contribute to thrombocytopenia [14] . This activity is modulated by ROCK (Rho-associated, coiled coil-containing kinase) that -like DIAPH1 -is an effector of the small GTP-binding protein RhoA [10] . Considering that DIAPH1 and ROCK control synergically the cytoskeleton reorganization during proplatelet formation, mutations in their genes could recapitulate similar phenotypes, and affected individuals with a suspicion of MYH9-RD, but negative at the MYH9 molecular screening, could carry DIAPH1 mutations [15] .
The activity of nonmuscle myosin IIA is regulated by phosphorylation, not only of its regulatory light chains but also of specific residues at the C-terminus of the MYH9 heavy chains. Among the different kinases involved is TRPM7 (transient receptor potential melastatin 7) that is likely to stabilize nonmuscle myosin IIA and inhibit bipolar filament formation [16] . In addition to being a kinase, TRPM7 is a cation channel that increases intracellular calcium levels and regulates magnesium ion homeostasis. Heterozygous missense mutations of its gene have been recently identified in three families with thrombocytopenia [17 && ]. Supported by studies on mouse model, the phenotype of the affected members is characterized by macrothrombocytopenia with impaired proplatelet formation. The defective platelet biogenesis is associated with cytoskeletal alterations that are rescued by magnesium ion supplementation or inhibition of nonmuscle myosin IIA activity, suggesting that both the TRPM7 activities are required for megakaryopoiesis and platelet formation.
To generate contractile forces, myosins interact with actin filaments, which in turn are cross-linked by dimers of alpha-actinin (ACTN1). Amino acid substitutions of ACTN1 are associated with a mild form of autosomal dominant macrothrombocytopenia (ACTN1-related thrombocytopenia; ACTN1-RT) accounting for approximately 4-5% of families suffering from inherited thrombocytopenias [18, 19] . It has recently been found that SNP rs117672662 of ACTN1 is associated with low platelet count and increased platelet volume at least in Hispanic/Latino Americans [20 && ]. This polymorphic marker lies within a megakaryocyte-specific enhancer in intron 1. Its two alleles (C > T) exhibit different affinity in binding HOXA5, which plays a role in hematopoiesis, and GATA1, a known transcription factor mutated in inherited thrombocytopenias. These data indicate that not only missense mutations but also variations of the ACTN1 transcriptional levels can affect the platelet production. Therefore, we cannot exclude that thrombocytopenia -as a complex trait -could be determined by combined effects of variants in more than one gene. As revealed by a series of genome-wide association studies, more than 60 genetic loci could explain differences of platelet count and size among individuals in the same population or among populations worldwide [20 && ,21] .
SIGNALING TRANSDUCTION PATHWAYS
A complex network of signaling events, involving platelet integrins, plays an important role in megakaryopoiesis and platelet production and function. A series of these events depends on SRC, a nonreceptor tyrosine kinase protein, whose first germline heterozygous mutation (p.Glu527Lys) has recently been identified in a large family [22 && ]. SRC is mainly in its inactive form due to phosphorylation of Tyr530. This closed configuration is maintained by interaction of Tyr530 and other residues, including Glu527, with the SH2 domain, suggesting that p.Glu527Lys is a gain-of-function mutation preventing SRC from self-inhibition [22 && ]. The affected individuals are characterized by thrombocytopenia with both small and large platelets, some with a grayish appearance due to lack of alpha-granules. Like individuals with gray platelet syndrome [23, 24] , they had myelofibrosis, but also edentulism before the third decade, and facial dysmorphisms. Megakaryocytes are increased in number and immature with dysplastic features such as hypolobulated nuclei. Moreover, they are almost unable to generate proplatelets, suggesting that the active form of SRC inhibits megakaryopoiesis and proplatelet formation. Both the blood and extrahematological features observed in patients have been recapitulated in zebrafish, supporting the role of SRC mutations in this novel syndromic form of inherited thrombocytopenia.
Of the inside-out and outside-in signaling players in platelets, the fibrinogen receptor alpha2b/ beta3 engages in a key bidirectional signaling. Mutations of ITGA2B and ITGB3, the two genes encoding for its subunits, cause Glanzmann thrombasthenia, an autosomal recessive bleeding disorder with normal platelet count. There are, however, gain-of-function variants associated with constitutive activation of the receptor, which being continuously internalized has a reduced expression level on platelet surface, and with impaired cytoskeleton reorganization [25] [26] [27] [28] . Individuals with these mutations have an autosomal dominant macrothrombocytopenia without aggregation defects, suggesting that regulation of the active/inactive state of the alpha2b/beta3 receptor has to be finely tuned for proper platelet biogenesis.
In this context relies FYB, a novel inherited thrombocytopenia gene encoding for a cytosolic adaptor molecule expressed in platelets and other blood cells. Participating in the activation of integrin alpha2b/beta3, FYB is likely to be involved in actin-cytoskeleton changes during proplatelet extension [29] . Indeed, homozygous loss-of-function mutations have been identified in two highly consanguineous families with a novel severe-tomoderate inherited thrombocytopenia associated with significant bleeding tendency [30 && ,31] . Platelets are small in size with increased basal level of P-selectin and PAC-1 and defective pseudopodium formation. The bone marrow aspirate showed no anomalies except for reduction of mature megakaryocytes, suggesting a defective maturation process. The role of FYB in platelet biogenesis is not completely understood. However, knockout mice recapitulate the phenotype, which -even if less severe than in humans -is characterized by moderate thrombocytopenia and increased rebleeding from tail wounds in spite of normal bleeding time [32] .
SLFN14: A NUCLEAR PROTEIN WITH POTENTIAL ENDORIBONUCLEASE ACTIVITY
Although the role of most of the inherited thrombocytopenia genes in megakaryopoieis and platelet production has being defined, that of SLFN14 (schlafen family member 14) remains unclear. Four heterozygous missense mutations, affecting its ATPbinding domain, are associated with a novel form of moderate inherited thrombocytopenia (SLFN14-related thrombocytopenia; SFLN14-RT) [33 && ,34 & ]. In three of the four SLFN14-RT families, bleeding tendency was more severe than expected on the basis of platelet count, with severe cutaneous bruising, prolonged bleeding from minor wounds, and other hemorrhagic manifestations [34 & ]. Indeed, like in individuals with mutations of FLI1, thrombocytopenia is associated with platelet dysfunction, as aggregation is reduced after stimulation with ADP, collagen, and PAR-1-activating peptide. Platelets are significantly defective in dense granules, leading to reduction of the ATP secretion; no other ultrastructural defects have been observed in platelets except for a slight increase of their size. SLFN14 is a member of the SLFN family of highly conserved proteins critical for proliferation and differentiation. Contrary to the other members, SLFN14 has a putative signal for nuclear location, where its endoribonuclease activity could regulate the rRNA and ribosome-associated mRNA cleavage [35] . The pathogenetic mechanisms responsible for SLFN14-RT remain obscure, though expression of SLFN14 is reduced up to 80% in patients' platelets when compared with controls, suggesting that the mutant proteins might be unstable and exert a dominant negative effect [34 & ]. The defective maturation of megakaryocytes and reduced proplatelet formation observed in patients are likely to be involved in the pathogenesis of thrombocytopenia [33 && ]. However, more investigations are required to further explore the role of SLFN14 in platelet biogenesis.
CONCLUSION
The majority of the inherited thrombocytopenias are autosomal dominant diseases characterized by mild/moderate reduction of platelet count usually not associated with other features. Lack of large families and distinct phenotypes prevent us from identifying genes using classical approaches, such as positional cloning. Instead, thanks to the success of NGS, the inherited thrombocytopenia genes are increasing rapidly. At present, mutations in more than 30 genes are known. Surprisingly, the novel genes account for only a few cases, suggesting that the genetic heterogeneity is wider than previously expected. Moreover, we cannot exclude that inherited thrombocytopenia could be the result of different predisposing variants in a polygenic context. Although application of the NGS technologies will have a strong impact not only in identifying novel genes but also in molecular genetic diagnosis, interpretation of data is not always obvious. Considering that inherited thrombocytopenias are mainly caused by heterozygous variants of apparently unknown significance, studies on identification of genes and/or mutations should be supported by functional investigations unraveling the pathogenetic effects and mechanisms.
